SCHEMBL1157971

SCHEMBL1157971

CCCCCCCCC=CCCCCCCC(C(=O)O)S(=O)(=O)O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TERT O14746 3/20 0.50
PTPN1 P18031 3/20 0.50
PPARG P37231 3/20 0.50
PPARD Q03181 3/20 0.50
PPARA Q07869 3/20 0.50
TOP1 P11387 3/20 0.50
MAPT P10636 2/20 0.50
BLM P54132 2/20 0.50
HSD17B10 Q99714 2/20 0.50
FABP4 P15090 2/20 0.50
GMNN O75496 1/20 0.50
USP2 O75604 1/20 0.50
LMNA P02545 1/20 0.50
CYP1A2 P05177 1/20 0.50
POLB P06746 1/20 0.50
CYP2C9 P11712 1/20 0.50
ALOX15 P16050 1/20 0.50
APEX1 P27695 1/20 0.50
CYP2C19 P33261 1/20 0.50
RECQL P46063 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9437263 1.00 TERT (0.50) TERTPTPN1PPARGPPARDPPARA
SCHEMBL9437261 1.00 TERT (0.50) TERTPTPN1PPARGPPARDPPARA
SCHEMBL1157969 1.00 TERT (0.50) TERTPTPN1PPARGPPARDPPARA
SCHEMBL9494969 0.95 ALDH1A1 (0.54) PPARGPPARDPPARAMAPTBLM
SCHEMBL10392507 0.90 FFAR1 (0.65) TERTPTPN1PPARGPPARDPPARA
SCHEMBL3495263 0.90 GPR84 (0.53) PPARDMAPTCHRM1TDP1FFAR1
SCHEMBL1157909 0.90 GPR84 (0.53) PPARDMAPTCHRM1TDP1FFAR1
SCHEMBL7609463 0.90 GPR84 (0.53) PPARDMAPTCHRM1TDP1FFAR1
SCHEMBL3495447 0.90 GPR84 (0.53) PPARDMAPTCHRM1TDP1FFAR1
SCHEMBL8574512 0.90 GPR84 (0.53) PPARDMAPTCHRM1TDP1FFAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1603932-B1 METHODS AND COMPOSITIONS FOR THE ENZYMATIC SYNTHESIS OF GANGLIOSIDES SENEB BIOSCIENCES INC (US) 2012-10-03 EP disclosed
US-7888331-B2 Ganglioside compositions and methods of use SENEB BIOSCIENCES, INC. (US) 2011-02-15 US disclosed
US-20070275908-A1 Methods and Compositions for the Enzymatic Synthesis of Gangliosides NEOSE TECHNOLOGIES, INC. (US) 2007-11-29 US disclosed
EP-1603932-A2 METHODS AND COMPOSITIONS FOR THE ENZYMATIC SYNTHESIS OF GANGLIOSIDES Neose Technologies, Inc. (US) 2005-12-14 EP disclosed
WO-2004080960-A2 METHODS AND COMPOSITIONS FOR THE ENZYMATIC SYNTHESIS OF GANGLIOSIDES NEOSE TECHNOLOGIES INC. (US) 2004-09-23 WO disclosed
US-6407072-B1 PROTEIN KINASE C INHIBITOR FIDIA S.P.A. (IT) 2002-06-18 US disclosed
US-20020072502-A1 Novel synthetic gangliosides NEURONYX, INC. 2002-06-13 US disclosed
WO-2002018401-A2 NOVEL SYNTHETIC GANGLIOSIDES NEURONYX, INC. (US) 2002-03-07 WO disclosed
WO-2002018402-A2 NOVEL SYNTHETIC GANGLIOSIDES NEURONYX, INC. (US) 2002-03-07 WO disclosed
US-5792858-A ACYLATING LYSOSPHINGOLIPIDS AND THEIR DERIVATIVES WITH AN ALIPHATIC ACID HAVING 2 TO 24 CARBON ATOMS, SUBSTITUTED BY ONE OR MORE POLAR GROUPS; PROTEIN-KINASE INHIBITOR, USEFUL FOR NERVOUS SYSTEM DISORDER TREATMENT FIDIA S.P.A. (IT) 1998-08-11 US disclosed
EP-0373038-B1 New lysosphingolipid derivatives FIDIA SPA (IT) 1997-03-05 EP disclosed
US-5523294-A THERAPY FOR NERVOUS SYSTEM DISORDERS FIDIA S.P.A. (IT) 1996-06-04 US disclosed
US-5519007-A ENZYME INHIBITORS OF KINASES FOR NERVOUS SYSTEM INHIBITORS FIDIA, S.P.A. (IT) 1996-05-21 US disclosed
EP-0373039-B1 New lysoganglioside derivatives FIDIA SPA (IT) 1994-04-06 EP disclosed
EP-0410883-A2 Di-lysogangliosides derivatives FIDIA S.p.A. (IT) 1991-01-30 EP disclosed
EP-0373039-A2 New lysoganglioside derivatives FIDIA S.p.A. (IT) 1990-06-13 EP disclosed
EP-0373038-A2 New lysosphingolipid derivatives FIDIA S.p.A. (IT) 1990-06-13 EP disclosed
US-4501658-A REMOVING TITANIUM MINERAL IMPURITIES FREEPORT KAOLIN COMPANY (US) 1985-02-26 US disclosed
US-4492628-A FROTH FLOTATIUON, DEFLOCCULATION OF TITANIUM IMPURITIES FREEPORT KAOLIN COMPANY (US) 1985-01-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275908-A1 Methods and Compositions for the Enzymatic Synthesis of Gangliosides SMPD1, GBA1, SMPD2 TERT 2686/4885PTPN1 4065/4885PPARG 2456/4885
US-20020072502-A1 Novel synthetic gangliosides NEU2, NEU1, SGMS2 TERT 3848/4885PTPN1 2047/4885PPARG 2403/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.